Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Real-time Quote. Real-time Tradegate - 02/23 11:02:27 am
80.99 EUR   +0.90%
02/20 SANOFI : Disclosure of trading in own shares
02/17 SANOFI : JHL Biotech Form Strategic Partnership
02/16 SANOFI : brings Toujeo to local market
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 01:58pm CET

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at mimosa.spencer@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
02/20 SANOFI : Disclosure of trading in own shares
02/17 SANOFI : JHL Biotech Form Strategic Partnership
02/16 REGENERON PHARMACEUTICALS : Appeals Court Grants Stay of Permanent Injunction fo..
02/16 SANOFI : Researchers' Work from Sanofi Pasteur Focuses on Hepatitis (Immunogenic..
02/16 SANOFI : Researchers from Sanofi Report Recent Findings in Osteoarthritis (I kap..
02/16 SANOFI : brings Toujeo to local market
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/16 IPSEN : Acquires Five Sanofi Consumer Healthcare Products
02/15 SANOFI -FEBRUARY 4&15 : World Cancer Days
02/15 IPSEN : to Acquire a Portfolio of Select Consumer Healthcare Products from Sanof..
More news
Sector news : Pharmaceuticals - NEC
10:23aDJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
08:49aDJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
08:49aDJBAYER : CEO Still Upbeat on Deal -- WSJ
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/22DJBAYER : Details Financing Plan for Monsanto Deal
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/22 Should Merck, BMS Fear Roche's Drug Becoming The I-O King?
02/21 PROTALIX BIOTHERAPEUTICS : New Institutional Ownership Swells Ahead Of Major Cat..
02/21 A Time To Buy Novo Nordisk
02/21 HEPATITIS B MARKET : Emerging Players Could Make The Difference
02/17 MannKind - Afrezza Sales Slip As New Sales Force Starts
Advertisement
Financials (€)
Sales 2017 36 457 M
EBIT 2017 9 209 M
Net income 2017 5 873 M
Debt 2017 4 692 M
Yield 2017 3,81%
P/E ratio 2017 14,79
P/E ratio 2018 16,83
EV / Sales 2017 2,97x
EV / Sales 2018 2,84x
Capitalization 103 711 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 82,3 €
Spread / Average Target 2,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI4.38%109 481
JOHNSON & JOHNSON3.86%325 158
ROCHE HOLDING LTD.5.98%210 992
PFIZER INC.3.51%203 836
NOVARTIS AG3.51%202 566
MERCK & CO., INC.11.23%180 014
More Results